Literature DB >> 17596512

LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Celine Deraison1, Chrystelle Bonnart, Frederic Lopez, Celine Besson, Ross Robinson, Arumugam Jayakumar, Fredrik Wagberg, Maria Brattsand, Jean Pierre Hachem, Goran Leonardsson, Alain Hovnanian.   

Abstract

LEKTI is a 15-domain serine proteinase inhibitor whose defective expression underlies the severe autosomal recessive ichthyosiform skin disease, Netherton syndrome. Here, we show that LEKTI is produced as a precursor rapidly cleaved by furin, generating a variety of single or multidomain LEKTI fragments secreted in cultured keratinocytes and in the epidermis. The identity of these biological fragments (D1, D5, D6, D8-D11, and D9-D15) was inferred from biochemical analysis, using a panel of LEKTI antibodies. The functional inhibitory capacity of each fragment was tested on a panel of serine proteases. All LEKTI fragments, except D1, showed specific and differential inhibition of human kallikreins 5, 7, and 14. The strongest inhibition was observed with D8-D11, toward KLK5. Kinetics analysis revealed that this interaction is rapid and irreversible, reflecting an extremely tight binding complex. We demonstrated that pH variations govern this interaction, leading to the release of active KLK5 from the complex at acidic pH. These results identify KLK5, a key actor of the desquamation process, as the major target of LEKTI. They disclose a new mechanism of skin homeostasis by which the epidermal pH gradient allows precisely regulated KLK5 activity and corneodesmosomal cleavage in the most superficial layers of the stratum corneum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596512      PMCID: PMC1951746          DOI: 10.1091/mbc.e07-02-0124

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  33 in total

1.  Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI.

Authors:  Thomas Lauber; Axel Schulz; Kristian Schweimer; Knut Adermann; Ute C Marx
Journal:  J Mol Biol       Date:  2003-04-18       Impact factor: 5.469

2.  Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A.

Authors:  Arumugam Jayakumar; Ya'an Kang; Kenji Mitsudo; Ying Henderson; Mitchell J Frederick; Mary Wang; Adel K El-Naggar; Ute C Marx; Katrina Briggs; Gary L Clayman
Journal:  Protein Expr Purif       Date:  2004-05       Impact factor: 1.650

3.  Thermodynamics and kinetics of single residue replacements in avian ovomucoid third domains: effect on inhibitor interactions with serine proteinases.

Authors:  M W Empie; M Laskowski
Journal:  Biochemistry       Date:  1982-05-11       Impact factor: 3.162

4.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

5.  LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.

Authors:  Emmanuelle Bitoun; Alessia Micheloni; Laurence Lamant; Chrystelle Bonnart; Alessandro Tartaglia-Polcini; Christian Cobbold; Talal Al Saati; Feliciana Mariotti; Juliette Mazereeuw-Hautier; Franck Boralevi; Daniel Hohl; John Harper; Christine Bodemer; Marina D'Alessio; Alain Hovnanian
Journal:  Hum Mol Genet       Date:  2003-07-29       Impact factor: 6.150

6.  Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7.

Authors:  Cécile Caubet; Nathalie Jonca; Maria Brattsand; Marina Guerrin; Dominique Bernard; Rainer Schmidt; Torbjörn Egelrud; Michel Simon; Guy Serre
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

7.  Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5-/- mice.

Authors:  Tao Yang; Dongcai Liang; Peter J Koch; Daniel Hohl; Farrah Kheradmand; Paul A Overbeek
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

8.  Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor.

Authors:  Peter Kreutzmann; Axel Schulz; Ludger Ständker; Wolf-Georg Forssmann; Hans-Jürgen Mägert
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-04-15       Impact factor: 3.205

9.  Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1.

Authors:  M Gu; J Rappaport; S H Leppla
Journal:  FEBS Lett       Date:  1995-05-22       Impact factor: 4.124

10.  Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.

Authors:  V M Gordon; K R Klimpel; N Arora; M A Henderson; S H Leppla
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.609

View more
  70 in total

Review 1.  Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases.

Authors:  Akiharu Kubo; Keisuke Nagao; Masayuki Amagai
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

2.  Identification of microRNAs associated with hyperthermia-induced cellular stress response.

Authors:  Gerald J Wilmink; Caleb L Roth; Bennett L Ibey; Norma Ketchum; Joshua Bernhard; Cesario Z Cerna; William P Roach
Journal:  Cell Stress Chaperones       Date:  2010-03-30       Impact factor: 3.667

Review 3.  Involvement of corneodesmosome degradation and lamellar granule transportation in the desquamation process.

Authors:  Akemi Ishida-Yamamoto; Mari Kishibe
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

4.  Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing.

Authors:  Chrystelle Bonnart; Céline Deraison; Matthieu Lacroix; Yoshikazu Uchida; Céline Besson; Aurélie Robin; Anaïs Briot; Marie Gonthier; Laurence Lamant; Pierre Dubus; Bernard Monsarrat; Alain Hovnanian
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

Review 5.  Atopic dermatitis in children: clinical features, pathophysiology, and treatment.

Authors:  Jonathan J Lyons; Joshua D Milner; Kelly D Stone
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

Review 6.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

7.  Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation.

Authors:  Ulrich auf dem Keller; Anna Prudova; Ulrich Eckhard; Barbara Fingleton; Christopher M Overall
Journal:  Sci Signal       Date:  2013-01-15       Impact factor: 8.192

8.  NIPAL4/ichthyin is expressed in the granular layer of human epidermis and mutated in two Pakistani families with autosomal recessive ichthyosis.

Authors:  Muhammad Wajid; Mazen Kurban; Yutaka Shimomura; Angela M Christiano
Journal:  Dermatology       Date:  2009-12-10       Impact factor: 5.366

Review 9.  Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.

Authors:  Sang Eun Lee; Se Kyoo Jeong; Seung Hun Lee
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

10.  Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.

Authors:  Anaïs Briot; Céline Deraison; Matthieu Lacroix; Chrystelle Bonnart; Aurélie Robin; Céline Besson; Pierre Dubus; Alain Hovnanian
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.